China's drug regulator approves Eli Lilly's obesity treatment orforglipron
LLY Lilly(Eli) & Co
$1437.29 +0.35%
View chart & analysis → - 1Eli Lilly shares rose 2.8% in Thursday premarket trading.
- 2China's overweight or obese population is projected to reach over 65% by 2030.
- 3Eli Lilly announced a $15 million share repurchase of RICHT common stock.
So what's the key point?
Eli Lilly's obesity treatment has received approval in China. This is good news for the company as China's obese population is expected to increase.
Source Investing.com +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.